Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ophthalmic medicament composition for forming low-irritation transparent emulsion formulation for surface immune adjustment and inflammation reduction of relevant tissue of eyes or eye periphery

A composition and drug technology, applied in the field of ophthalmic pharmaceutical compositions, can solve problems such as obstructing vision and unfavorable eyes

Active Publication Date: 2010-12-01
RXVISION PHARMA CO LTD
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the existing emulsion-type ophthalmic pharmaceutical composition maintains a milky white and opaque state when it is administered, which may cause the problem of obstructing vision and is not conducive to applying to the eyes.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic medicament composition for forming low-irritation transparent emulsion formulation for surface immune adjustment and inflammation reduction of relevant tissue of eyes or eye periphery

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] Embodiments of the present invention are described in detail below, and the embodiments described below are exemplary, and are only used to explain the present invention, but not to limit the present invention.

[0018] The present invention is a new ophthalmic pharmaceutical composition, which involves compounds that are not easily soluble in water, such as cyclosporine. The ophthalmic pharmaceutical composition of the present invention is formed as a cyclosporine emulsion containing propylene glycol (propylene glycol) and polyoxyethylene castor oil derivatives, which can provide a high degree of comfort and low irritation.

[0019] The ophthalmic pharmaceutical composition of the present invention is in the form of an ophthalmic emulsion, which is formed as a low-irritant transparent emulsion that is easy to enter into the sensitive visual area, and its components include cyclosporine, propylene glycol, polyoxyalkylene 35 castor oil, polyethylene Alcohol and pure wate...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an ophthalmic medicament composition for forming a low-irritation transparent emulsion formulation for the surface immune adjustment and inflammation reduction of the relevant tissue of eyes or eye periphery. The ophthalmic medicament composition is used for treating the inflammatory reaction of a serious keratoconjunctivitis sicca and cornea epithelium pathological change patient, forms an emulsion formulation, contains at least one ciclosporin, propylene glycol and polyoxyethylene castor oil derivative, such as polyoxyethylene 35 castor oil derivative, and the like, is transparent, has the characteristics of low irritation, stability and no crystallization phenomenon and is suitable for more sensitive areas, such as eye tissue, and the like.

Description

technical field [0001] The present invention relates to an ophthalmic pharmaceutical composition, in particular to an ophthalmic pharmaceutical composition which is formed into a low-irritant transparent emulsion dosage form to provide surface immune regulation and anti-inflammation for eyes or related organs or tissues. Background technique [0002] The cyclosporine group is a group of non-polar cyclic oligopeptides (oligopeptides) with immunosuppressive activity, while cyclosporine A (cyclosporine A) and several other cyclosporine B (cyclosporine B), which are identified as minor metabolites, Cyclosporine C (cyclosporine C), cyclosporine D (cyclosporine D), cyclosporine E (cyclosporine E), and even cyclosporine H (cyclosporine H) all belong to the cyclosporine group. These cyclosporine groups are composed of 11 peptides. U.S. Patent No. 4839342 (U.S. Pat. No. 4,839,342) discloses a technique for effectively treating immune keratoconjunctivitis sicca (keratoconjunctivitis ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/13A61K9/107A61K47/44A61K47/10A61P27/02
Inventor 萧义明洪伊珊吴佩桦陈嘉真张天赐
Owner RXVISION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com